---
title: "Silexion Therapeutics to Attend BIO International Convention 2026 | SLXN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289964653.md"
description: "Silexion Therapeutics announced that its management, including CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention in San Diego from June 22-25. The company will host one-on-one meetings with interested parties during the event. Silexion is a clinical-stage biotech firm developing RNAi therapies for KRAS-driven cancers."
datetime: "2026-06-16T12:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289964653.md)
  - [en](https://longbridge.com/en/news/289964653.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289964653.md)
generator: "portal-rs"
---

# Silexion Therapeutics to Attend BIO International Convention 2026 | SLXN Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company’s Chief Executive Officer, Ilan Hadar, and the Company’s Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA. 

Silexion’s management will host one-on-one meetings during the BIO Convention. Interested parties should contact Silexion company representative to arrange a meeting.

**About Silexion Therapuetics**  
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product, which showed a positive trend in comparison to the control of chemotherapy alone, and is currently advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), towards clinical trials in Israel and the European Union. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

**Company Contact:**  
Silexion Therapeutics Corp  
Ms. Mirit Horenshtein Hadar, CFO  
mirit@silexion.com  

**Investor Relations**  
Arx Investor Relations  
North American Equities Desk  
silexion@arxhq.com

Chuck Padala  
LifeSci Advisors  
Chuck@lifesciadvisors.com

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancers](https://longbridge.com/en/news/294830800.md)
- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md)
- [HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy | HCM Stock News](https://longbridge.com/en/news/297858626.md)
- [Rein Therapeutics CEO to present at Cantor Global Healthcare Conference](https://longbridge.com/en/news/297952106.md)
- [Incyte (INCY) Stock Could Be 31% Stretched Following KRAS Data Buzz](https://longbridge.com/en/news/297419518.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**